Celsis Seeks Injunction Against Invitrogen for LiverPool(TM) Patent Infringement

BALTIMORE, June 30, 2010 - Celsis In Vitro, Inc. (Celsis IVT) announced today that it has filed a
patent infringement lawsuit against Invitrogen Corporation (Invitrogen) and
CellzDirect, Inc. (CellzDirect) in the United States District Court for the
Northern District of Illinois in Chicago and has moved for a preliminary
injunction. Invitrogen, the parent of CellzDirect, is itself a wholly-owned
subsidiary of Life Technologies of Carlsbad, California. The complaint
alleges that certain processes and methods performed by CellzDirect
associated with its in vitro drug testing services and its pooled
cryopreserved hepatocyte products infringe one or more claims of U.S. Patent
No. 7,604,929 (the '929 patent). The complaint also alleges that Invitrogen
is selling these infringing products and services, as well as inducing
infringement of the '929 patent, and seeks monetary damages and injunctive
relief.

Last month, Celsis IVT successfully reached a settlement agreement with
XenoTech, LLC, Sekisui Chemical Co. Ltd., and Sekisui Medical Co. Ltd. in a
similar patent infringement lawsuit involving the '929 patent. Celsis is
represented by Jordan Sigale and Adam Kelly of Loeb & Loeb LLP.

The '929 patent relates to processes and methods for producing
cryopreserved hepatocytes. In general, this technology combines hepatocytes
from multiple donors to create large lots with targeted activity levels, the
result of which is a product that speeds up decision making and reduces the
time and cost of drug research. Since 2005, Celsis IVT has used this novel
technology to create its unique LiverPool(TM) products for drug discovery
research. Major pharmaceutical companies around the world have incorporated
these LiverPool products into their standard research protocols. Research
conducted with LiverPool has confirmed its outstanding efficacy as a research
tool in numerous ADME-Tox assays, including metabolic stability and clearance
studies. Additional LiverPool product information is available online at
www.celsis.com/liverpool.

"Celsis believes that innovations are the lifeblood of the life sciences
industry. Advancements must be protected and respected if we are to further
the cause of cost-effective drug discovery," said Jay LeCoque, CEO of Celsis.
"We are extremely disappointed that we have been forced into this litigation,
but the predatory pricing employed by Invitrogen and CellzDirect suggests a
serious attempt to erode our patent-protected market position for the
LiverPool product line." He added, "These tactics are lowering, as well as
undermining, the perceived value of new product innovations and inventions.
We remain hopeful that the defendants will realize the serious impact of such
a precedent on the entire life sciences industry, and that they will work
with us to properly resolve this issue."

About Celsis IVT

Celsis IVT, a subsidiary of Celsis Holdings, Inc., itself a subsidiary of
Celsis International Ltd., is the premier world provider of specialized in
vitro products for the study of metabolism, drug-drug interactions and
toxicity in drug discovery and development. Since 1990, pharmaceutical and
biotechnology companies have relied on Baltimore-based Celsis IVT for quality
in vitro products for lead optimization. Celsis IVT products deliver faster
time to results, enabling more productive and cost-effective research. Celsis
IVT's patented LiverPool products, cryo-plateable hepatocytes (the world's
largest inventory) and other ADMET research tools are available worldwide.
Visit www.celsis.com/ivt.

About Celsis International Ltd

Chicago-based Celsis International Ltd is a leading global provider of
innovative life science products and laboratory services to the
pharmaceutical and consumer products industries. Celsis divisions
deliver substantial time and cost savings to customers while ensuring
product quality and safety. Celsis' extensive client base
includes leading pharmaceutical and consumer products companies, including
the top 25 pharmaceutical companies worldwide. Details at www.celsis.com.

Adam Kelly of Loeb & Loeb, +1-312-464-3138, akelly at loeb.com, for Celsis In Vitro, Inc.